<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313014</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3015</org_study_id>
    <nct_id>NCT00313014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the effectiveness and tolerability of the
      buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal
      system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back
      pain currently treated with oral opioids. The double-blind treatment intervention duration is
      12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will
      be provided to all subjects in addition to study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical
      experience indicating it to be safe and effective in a variety of therapeutic situations for
      the relief of moderate to severe pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to administrative reasons unrelated to efficacy or safety.
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.</measure>
    <time_frame>Last 24 hours score at weeks 4, 8, 12 of the double-blind phase</time_frame>
    <description>Subjects were evaluated during the double-blind phase for &quot;average pain over the last 24 hours&quot; prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Number of Supplemental Analgesic Tablets</measure>
    <time_frame>Double-blind phase (84 days)</time_frame>
    <description>The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI) Score (V 2.0)</measure>
    <time_frame>Weeks 4, 8, 12</time_frame>
    <description>The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.
The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.</measure>
    <time_frame>Weeks 4, 8, 12 of the double-blind phase</time_frame>
    <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).
Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">660</enrollment>
  <condition>Back Pain Lower Back Chronic</condition>
  <arm_group>
    <arm_group_label>BTDS 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTDS 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone Immediate-Release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.</description>
    <arm_group_label>BTDS 5</arm_group_label>
    <other_name>Butrans™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
    <arm_group_label>BTDS 20</arm_group_label>
    <other_name>Butrans™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Immediate-Release</intervention_name>
    <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
    <arm_group_label>Oxycodone Immediate-Release</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  low back pain for 3 months or longer, confirmed by radiographic evidence.

          -  receiving a stable dose of an opioid analgesic for low back pain.

        Exclusion Criteria:

          -  taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days
             of enrollment.

          -  requiring frequent analgesic therapy for chronic condition(s), in addition to low back
             pain.

        Other protocol-specific exclusion/inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gold Coast Research LLC, Weston, FL, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Pain Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinical Intervention Program</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winston Physician Services, LLC</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Therapeutics</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hot Springs Pain Clinic</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NuLife Clinical Research, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research Corp</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Network</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shreenath Clinical Service</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Calif at Davis, Med Ctr, Pain Management Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Colorado Clinic</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiefland Medical Center</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research, Inc.</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Study Institute</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Inc.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Inc.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research, LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Medical Research Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Knee &amp; Shoulder Clinic</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Care Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Arthritis and Osteoporosis Center</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain and Rehabilitation Clinic of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GFI Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Clinics</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTT, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Biomedical Research, LLC</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Clinical Trial Management Inc.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Associates, Inc.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trials, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center of Louisiana</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Care Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>11070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Michigan Clinical Research &amp; Consulting, Inc.</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research, Inc.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthCare Research</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>North Las Vegas</city>
        <state>Nevada</state>
        <zip>89030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain and Orthopedic Neurology , Charlotte Spine Center,</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Medical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triangle Orthopaedic Associates</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmquest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedArk Clinical Research</name>
      <address>
        <city>Morgantown</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Bismark</city>
        <state>North Dakota</state>
        <zip>58502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COR Clinical Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Services</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Research</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Pain Specialists</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Pennsylvania Clinical Research</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioMedical Research Associates</name>
      <address>
        <city>Shippensburg</city>
        <state>Pennsylvania</state>
        <zip>17257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center Clinical Research</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>29200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>28860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Center</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Clinic</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Cities Medical Research</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galenos Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Team Research of Central Texas</name>
      <address>
        <city>Harker Heights</city>
        <state>Texas</state>
        <zip>76548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unlimited Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Medical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network Oaks Medical Center</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77386</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N. Texas Neuro Research</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Medical Center</name>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <zip>53575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <results_reference>
    <citation>Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011 Nov;12(11):1163-73. doi: 10.1016/j.jpain.2011.06.003. Epub 2011 Jul 31.</citation>
    <PMID>21807566</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2006</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2006</study_first_posted>
  <results_first_submitted>July 28, 2010</results_first_submitted>
  <results_first_submitted_qc>September 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2010</results_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low back pain</keyword>
  <keyword>opioid</keyword>
  <keyword>transdermal</keyword>
  <keyword>Butrans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study began with first patient first visit (FPFV) on 25-Feb-2004 to last patient last visit (LPLV) on 23-Sep-2005, at 75 medical/research sites in the United States.</recruitment_details>
      <pre_assignment_details>Prerandomization: screening period [Prospective assessment: subjects were assessed to ensure compliance with all inclusion/exclusion criteria]. Opioid taper segment: assessed the severity of the subject’s low back pain upon analgesic medication discontinuation. Open-label run-in period: identified subjects whose pain was controlled with BTDS 20.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="P2">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="P3">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="B2">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="B3">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="219"/>
            <count group_id="B3" value="220"/>
            <count group_id="B4" value="660"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="12.88"/>
                    <measurement group_id="B2" value="50.4" spread="11.93"/>
                    <measurement group_id="B3" value="49.5" spread="12.37"/>
                    <measurement group_id="B4" value="50.0" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.</title>
        <description>Subjects were evaluated during the double-blind phase for &quot;average pain over the last 24 hours&quot; prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)</description>
        <time_frame>Last 24 hours score at weeks 4, 8, 12 of the double-blind phase</time_frame>
        <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.</title>
          <description>Subjects were evaluated during the double-blind phase for &quot;average pain over the last 24 hours&quot; prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)</description>
          <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="0.075"/>
                    <measurement group_id="O2" value="6.46" spread="0.084"/>
                    <measurement group_id="O3" value="6.46" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="0.075"/>
                    <measurement group_id="O2" value="2.91" spread="0.075"/>
                    <measurement group_id="O3" value="2.74" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="0.149"/>
                    <measurement group_id="O2" value="3.40" spread="0.128"/>
                    <measurement group_id="O3" value="3.14" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="0.162"/>
                    <measurement group_id="O2" value="3.35" spread="0.140"/>
                    <measurement group_id="O3" value="3.24" spread="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.179"/>
                    <measurement group_id="O2" value="3.35" spread="0.139"/>
                    <measurement group_id="O3" value="3.26" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P value was 2-sided and performed at the 5% error level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures mixed linear model with treatment, time, and time by treatment interaction as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.163</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P value was 2-sided and performed at the 5% error level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures mixed linear model with treatment, time, and time by treatment interaction as fixed effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.161</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Number of Supplemental Analgesic Tablets</title>
        <description>The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase</description>
        <time_frame>Double-blind phase (84 days)</time_frame>
        <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Number of Supplemental Analgesic Tablets</title>
          <description>The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase</description>
          <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>tablets</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.12"/>
                    <measurement group_id="O2" value="3.3" spread="0.13"/>
                    <measurement group_id="O3" value="3.5" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.006</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
            <estimate_desc>The analysis was based on the number of subjects who took &gt; 1 tablet of supplemental analgesia.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.158</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>The analysis was based on the number of subjects who took &gt; 1 tablet of supplemental analgesia.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Disability Index (ODI) Score (V 2.0)</title>
        <description>The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.
The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)</description>
        <time_frame>Weeks 4, 8, 12</time_frame>
        <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>Oswestry Disability Index (ODI) Score (V 2.0)</title>
          <description>The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.
The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)</description>
          <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.80" spread="1.066"/>
                    <measurement group_id="O2" value="33.04" spread="1.019"/>
                    <measurement group_id="O3" value="30.79" spread="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.69" spread="1.245"/>
                    <measurement group_id="O2" value="34.27" spread="1.094"/>
                    <measurement group_id="O3" value="31.64" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.30" spread="1.392"/>
                    <measurement group_id="O2" value="33.06" spread="1.231"/>
                    <measurement group_id="O3" value="32.96" spread="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.065</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.55</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.031</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.</title>
        <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).
Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
        <time_frame>Weeks 4, 8, 12 of the double-blind phase</time_frame>
        <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.</title>
          <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).
Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
          <population>Full Analysis Population (N = 660) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.67" spread="2.025"/>
                    <measurement group_id="O2" value="34.65" spread="1.607"/>
                    <measurement group_id="O3" value="38.10" spread="1.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.28" spread="2.264"/>
                    <measurement group_id="O2" value="35.69" spread="1.721"/>
                    <measurement group_id="O3" value="39.17" spread="1.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.85" spread="2.376"/>
                    <measurement group_id="O2" value="33.65" spread="1.941"/>
                    <measurement group_id="O3" value="41.60" spread="2.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that the BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed linear model: treatment, time as fixed effects, screening, prerandomization sleep disturbance subscale as covariates; subject as a random effect</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.735</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.64</ci_lower_limit>
            <ci_upper_limit>-2.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between BTDS 20 or oxycodone HCl immediate-release 40 mg with respect to BTDS 5. The alternative hypothesis was that BTDS 20 arm was different from the BTDS 5 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.121</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.709</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.01</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events occurring after the signing of the informed consent up to end of study and 7 days after, discontinuation, or serious AEs occurring up to 30 days following the last study visit were followed until the AE or sequelae resolved or stabilized.</time_frame>
      <desc>AEs were learned of by spontaneous reports, subject interview, and daily diary.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="E2">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="E3">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
        </group>
        <group group_id="E4">
          <title>Open-label Run-in Period, BTDS 10/20</title>
          <description>Open-label BTDS 10 or 20 mcg/h applied for 7-day wear</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 5.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia - DEATH</sub_title>
                <description>Death Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Brain arteriovenous malformation</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Intractable vomiting</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Chest pressure</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Worsening chronic cholecycstitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Left lower lobe pneumonia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Right heel diabetic foot abscess</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Right heel infection</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cocaine toxicity - DEATH</sub_title>
                <description>Death Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Drowning - DEATH</sub_title>
                <description>Death Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Fracture distal right radius</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased total bilirubin</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herniated disc</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Clear cell carcinoma left ovary metastatic</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity lumbar radiculopathy</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis with diminution of L4-5</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Nerve entrapment</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Acute axonal motor neuropathy</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression worsening</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stones</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute bronchospasm</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Acute exacerbation of chronic obstructive pulmonary disease (COPD)</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Depressed respiration</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Exacerbation of COPD</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Left pleural effusion</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Hematoma, right thigh</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>MedDRA version 5.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="389" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="174" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="124" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="1160"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="1160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>BUP3015 was terminated early due to administrative reasons unrelated to efficacy or safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Leader, Medical Director</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

